Anti-Hu CD33 Purified

Anti-Hu CD33 Purified

• Background: CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia.
• Specifications: The mouse monoclonal antibody WM53 reacts with an extracellular epitope of CD33, a 67 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells it is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.
• CAS Number: 9007-83-4
• Certification: RUO
• Host: Mouse
• Species Reactivity: Non-human primates, Human
• Immunogen: Human AML cells
• Target Antigen: CD33
• Isotype: IgG1
• Clone: WM53
• Applications: Immunohistochemistry (frozen sections): Acetone fixation. Flow cytometry: Recommended dilution: 1-4 µg/mL
• Validated Applications: FC, IP, WB, IHC-F, ICC, MC-CyTOF
• Concentration: 1 mg/mL
• Format: Purified
• Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
• References & Citations: *Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB, Quintanilla-Cecconi AM, García-Alonso A, Alvarez-López DM, García-Pe241arrubia P: A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006 Jan79(1):46-58., URL: http://www.ncbi.nlm.nih.gov/pubmed/16380601 ,*Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P: Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005 Feb 1105(3):1256-64., URL: http://www.ncbi.nlm.nih.gov/pubmed/15388576 ,*Schenk M, Bouchon A, Birrer S, Colonna M, Mueller C: Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine. J Immunol. 2005 Jan 1174(1):517-24., URL: http://www.ncbi.nlm.nih.gov/pubmed/15611278 ,*Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F, Lanza GA, Contemi AM, Leone G, Crea F: Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005 Jun26(12):1196-204., URL: https://www.ncbi.nlm.nih.gov/pubmed/15734770,*Hernández-López C, Varas A, Sacedón R, Jiménez E, Muñoz JJ, Zapata AG, Vicente A: Stromal cell-derived factor 1/CXCR4 signaling is critical for early human T-cell development. Blood. 2002 Jan 1599(2):546-54., URL: https://www.ncbi.nlm.nih.gov/pubmed/11781237,*Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, Pitto A, Bacigalupo A, Moretta L, Mingari MC: Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci U S A. 2001 May 898(10):5764-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/11320212,*Shin YK, Choi EY, Kim SH, Chung J, Chung DH, Park WS, Jung KC, Kim HS, Park S, Kim HJ, Park MH, Min CK, Kim CC, Park SH: Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am J Pathol. 2001 Apr158(4):1473-80., URL: https://www.ncbi.nlm.nih.gov/pubmed/11290565,*Bradstock KF, Kirk J, Grimsley PG, Kabral A, Hughes WG: Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations. Br J Haematol. 1989 Aug72(4):512-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/2673329,*Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H: Further characterization of human myeloid antigens (gp160,95 gp150 gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol. 1988 Jun69(2):163-71., URL: https://www.ncbi.nlm.nih.gov/pubmed/2455535,*Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Berndt MC: Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33). Dis Markers. 1987 Dec5(4):215-25. , URL: https://www.ncbi.nlm.nih.gov/pubmed/3502990,
• Other References: *Walter RB, Häusermann P, Raden BW, Teckchandani AM, Kamikura DM, Bernstein ID, Cooper JA: Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface Receptor. Traffic. 2007 Dec 18, URL: https://www.ncbi.nlm.nih.gov/pubmed/18062779?ordin,*Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA: CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood. 2007 Feb 1109(3):1061-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/17008544?ordin,*Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML: The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999 Nov29(11):3440-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/10556798?ordin,
• Storage Conditions: Store at 2-8°C. Do not freeze.